Evidence-Based Use of Hematopoietic Cytokines in Clinical Oncology

  • George D. Demetri
Part of the Developments in Oncology book series (DION, volume 80)

Abstract

The history of medicine is replete with examples which show how certain new technology and new therapeutics improve clinical outcomes. The introduction of hematopoietic cytokines into the clinical practice of oncology represents one of the more interesting recent examples of technologic innovation translating into clinical therapeutics. The corporate-sponsored research that tested these recombinant agents in humans set new standards for rapidly turning laboratory findings such as cloned human cytokine genes into useful therapeutic compounds such as recombinant human granulocyte colony-stimulating factor (G-CSF), recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), and recombinant human erythropoietin (epoetin alfa, EPO). However, once G-CSF, GM-CSF, and EPO were commercially available for broad use by oncologists, it became clear that the optimal and appropriate use of these agents required more study and analysis. It is important also to note that hematopoietic cytokines are not unique in cancer medicine: many new cancer therapeutic agents are very expensive, and after initial regulatory approval, the field of oncology continually re-assesses the use of new agents. Often, for cytotoxic chemotherapies, this involves more broad use of a new agent outside of the initial tumor type for which the drug was approved (so-called “off label” use in practice). Such expansion of chemotherapy use can yield important new uses for a drug.

Keywords

Placebo Toxicity Lymphoma Leukemia Anemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bodey GP, Buckley M, Sathe YS,Freireich E: Quantitative relationship between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 64: 328–340, 1966PubMedGoogle Scholar
  2. 2.
    Gaydos LA, Freireich EJ, Mantel N, et al: The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 266: 905, 1962PubMedCrossRefGoogle Scholar
  3. 3.
    Hersh EM, Bodey GP, Niles B A,Freireich EJ: Causes of death in acute leukemia — a ten year study of 414 patients from 1954–1963. JAMA 193: 99, 1965CrossRefGoogle Scholar
  4. 4.
    Frei III E,Canellos GP: Dose: a critical factor in cancer chemotherapy. Am J Medicine 69: 585–594, 1980CrossRefGoogle Scholar
  5. 5.
    Henderson I, DF H,Gelman R: Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 6: 1501–1515, 1988PubMedGoogle Scholar
  6. 6.
    Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281–1288, 1984PubMedGoogle Scholar
  7. 7.
    Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy fo stage II, node-positive breast carcinoma. N Engl J Med 330: 1253–1257, 1994.PubMedCrossRefGoogle Scholar
  8. 8.
    Siu LL and Tannock IF: Chemotherapy dose escalation: Case Unpröven (editorial). J Clin Oncol 15. 2765–2768, 1997PubMedGoogle Scholar
  9. 9.
    Savarese DMF, Hsieh CC, Stewart FM: Clinical Impact of Chemotherapy Dose Escalation in Patients With Hematologic Malignancies and Solid Tumors. J Clin Oncol 15:2981–2995, 1997.PubMedGoogle Scholar
  10. 10.
    Moore MAS: Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 78: 1–19, 1991PubMedGoogle Scholar
  11. 11.
    Demetri GD, Griffin JD: Granulocyte colony-stimulating factor and its receptor. Blood 78: 2791–2808, 1991Google Scholar
  12. 12.
    Lieschke GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (parts I and II). New Engl J Med 327: 28–35, 99–106, 1992PubMedCrossRefGoogle Scholar
  13. 13.
    Metcalf D: Hematopoietic Regulators: Redundancy or Subtlety? Blood 82:3515–3523,1993PubMedGoogle Scholar
  14. 14.
    Groopman JE, Mitsuyasu RT, DeLeo MJ, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 317: 593–8, 1987PubMedCrossRefGoogle Scholar
  15. 15.
    Antman K, Griffin J, Elias A, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319: 593–598, 1988PubMedCrossRefGoogle Scholar
  16. 16.
    Gabrilove JL, Jakubowski A, Fain K, et al: Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium._. J Clin Invest 82: 1454–61, 1988PubMedCrossRefGoogle Scholar
  17. 17.
    Morstyn G, Campbell L, Souza LM, et al: Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1: 667–72, 1988PubMedCrossRefGoogle Scholar
  18. 18.
    Vadhan-Raj S, Keating M, LeMaistre A, et al: Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545–1552, 1987PubMedCrossRefGoogle Scholar
  19. 19.
    Vadhan-Raj S, Buescher S, Broxmeyer HE, et al: Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor. N Engl J Med 319: 1628–34, 1988PubMedCrossRefGoogle Scholar
  20. 20.
    Negrin RS, Haeuber DH, Nagler A, et al: Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial. Ann Intern Med 110: 976–84, 1989PubMedGoogle Scholar
  21. 21.
    Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325: 164–170, 1991PubMedCrossRefGoogle Scholar
  22. 22.
    Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A: 319–324, 1993PubMedCrossRefGoogle Scholar
  23. 23.
    Nemunaitis J, Rabinowe SN, Singer JW, et al: Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphopid cancer. N Engl J Med 324: 1773–1778, 1991PubMedCrossRefGoogle Scholar
  24. 24.
    Abels R: Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A: S2-S8, 1993 (suppl 2)PubMedCrossRefGoogle Scholar
  25. 25.
    Maher D, Green M, Bishop J, et al: Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 121: 492–501, 1994.PubMedGoogle Scholar
  26. 26.
    Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218–1234, 1997PubMedGoogle Scholar
  27. 27.
    Demetri GD, Kris M, Wade J, et al: Quality-of-Life Benefit in Chemotherapy Patients Treated with Epoetin Alfa is Independent of Disease Response or Tumor Type: Results From a Prospective Community Oncology Study. J Clin Oncol (1998, in press)Google Scholar
  28. 28.
    ASCO Ad Hoc Committee on Hematopoietic Growth Factors: American Society of Clinical Oncology Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Practice Guidelines. J Clin Oncol 12:2471–2508, 1994.Google Scholar
  29. 29.
    ASCO Ad Hoc Committee on Hematopoietic Growth Factors: Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines J Clin Oncol 16: 1957–1960, 1996.Google Scholar
  30. 30.
    Lyman GH, Lyman CG, Sanderson RA,Balducci L: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst USA 85: 488–493, 1993CrossRefGoogle Scholar
  31. 31.
    Morstyn G, Campbell L, Lieschke G, et al: Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 7:1554–62, 1989PubMedGoogle Scholar
  32. 32.
    Gianni A, Bregni M, Siena S, et al: Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin’s lymphoma. J Clin Oncol 8: 768–778, 1990PubMedGoogle Scholar
  33. 33.
    Neidhart JA, Mangalik A, Stidley CA, et al: Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy. J Clin Oncol 10: 1460–1469, 1992PubMedGoogle Scholar
  34. 34.
    Hartmann LC, Tschetter LK, Habermann TM, et al: Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336:1776–1780, 1997PubMedCrossRefGoogle Scholar
  35. 35.
    Rowe JM, Anderson JW, Mazza J J, et al. A randomized placebo-controlled Phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (El490). Blood 86:457–462, 1995.PubMedGoogle Scholar
  36. 36.
    Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1671–1677, 1995.PubMedCrossRefGoogle Scholar
  37. 37.
    Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678–1683, 1995.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • George D. Demetri

There are no affiliations available

Personalised recommendations